Therapeutic options for advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer: a Bayesian network secondary analysis

The most favorable treatments for advanced EGFR-mutant NSCLC are less indicated. Forty-one studies were eligible for this Bayesian network secondary analysis. For PFS, erlotinib (Erlo)+bevacizumab (Bev) (HR 0.26, 95% CrI: 0.08-0.75 vs placebo), osimertinib (Osi) (HR 0.29, 0.11-0.70 vs placebo), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Xinmin, Wan, Xuan, Xu, Jun, Wang, Hui, Chen, Hua, Zeng, Qinghua, Zhang, Wenxiong, Zhao, Binghao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202525/
https://www.ncbi.nlm.nih.gov/pubmed/32324592
http://dx.doi.org/10.18632/aging.103066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202525/
https://www.ncbi.nlm.nih.gov/pubmed/32324592
http://dx.doi.org/10.18632/aging.103066

Ejemplares similares